Lineage Cell Therapeutics Inc (AMEX: LCTX) is 28.44% higher on its value in year-to-date trading and has touched a low of $0.84 and a high of $1.57 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LCTX stock was last observed hovering at around $1.31 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $1.40, the stock is 16.76% and 25.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.33 million and changing 6.87% at the moment leaves the stock 15.54% off its SMA200. LCTX registered 0.72% gain for a year compared to 6-month loss of 20.69%. The firm has a 50-day simple moving average (SMA 50) of $25.87 and a 200-day simple moving average (SMA200) of -$9.63.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 28.44% gain in the last 1 month and extending the period to 3 months gives it a 25.00%, and is 14.75% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.92% over the week and 9.72% over the month.
Lineage Cell Therapeutics Inc (LCTX) has around 75 employees, a market worth around $263.94M and $8.95M in sales. Profit margin for the company is -240.20%. Distance from 52-week low is 66.39% and -10.77% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.81%).
Lineage Cell Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $1.36M over the same period.The EPS is expected to shrink by -1.19% this year, but quarterly earnings will post 81.90% year-over-year. Quarterly sales are estimated to shrink -32.30% in year-over-year returns.
143 institutions hold shares in Lineage Cell Therapeutics Inc (LCTX), with institutional investors hold 45.86% of the company’s shares. The shares outstanding are 188.53M, and float is at 187.49M with Short Float at 5.32%. Institutions hold 43.96% of the Float.
The top institutional shareholder in the company is Broadwood Capital, Inc. with over 34.94 million shares valued at $49.26 million. The investor’s holdings represent 19.96% of the LCTX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 9.01 million shares valued at $12.71 million to account for 5.15% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 7.16 million shares representing 4.09% and valued at over $10.1 million, while Defender Capital, LLC holds 2.92% of the shares totaling 5.11 million with a market value of $7.2 million.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
The most recent transaction is an insider purchase by BAILEY DON M, the company’s Director. SEC filings show that BAILEY DON M bought 96,155 shares of the company’s common stock on Feb 08 ’24 at a price of $1.04 per share for a total of $0.1 million. Following the purchase, the insider now owns 0.16 million shares.
Lineage Cell Therapeutics Inc disclosed in a document filed with the SEC on Feb 06 ’24 that BROADWOOD PARTNERS, L.P. (Director) bought a total of 6,730,770 shares of the company’s common stock. The trade occurred on Feb 06 ’24 and was made at $1.04 per share for $7.0 million. Following the transaction, the insider now directly holds 41.67 million shares of the LCTX stock.
Still, SEC filings show that on Dec 29 ’23, Jayasuriya Anula (Director) acquired 10,000 shares at an average price of $1.09 for $10900.0. The insider now directly holds 10,000 shares of Lineage Cell Therapeutics Inc (LCTX).
